Carcinogenesis

You have full text access to this OnlineOpen article

The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice

  1. Weidong Su1,
  2. Brian M. Necela1,
  3. Kosaku Fujiwara2,
  4. Shinichi Kurakata2,
  5. Nicole R. Murray1,
  6. Alan P. Fields1,
  7. E. Aubrey Thompson1,†,*

Article first published online: 10 JUN 2008

DOI: 10.1002/ijc.23640

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 5, pages 991–997, 1 September 2008

Additional Information

How to Cite

Su, W., Necela, B. M., Fujiwara, K., Kurakata, S., Murray, N. R., Fields, A. P. and Thompson, E. A. (2008), The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice. Int. J. Cancer, 123: 991–997. doi: 10.1002/ijc.23640

Author Information

  1. 1

    Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL

  2. 2

    Daiichi Sankyo Inc., Tokyo, Japan

  1. †

    Fax: +904-953-6233.

*Department of Cancer Biology, Mayo Clinic, Griffin Cancer Research Bld., Rm 214, 4500 San Pablo Rd., Jacksonville, FL 32224, USA

Publication History

  1. Issue published online: 17 JUN 2008
  2. Article first published online: 10 JUN 2008
  3. Manuscript Accepted: 17 MAR 2008
  4. Manuscript Received: 9 NOV 2007

Funded by

  • Daiichi Sankyo, Inc.
  • National Cancer Center, National Institutes of Health, United States Public Health Service. Grant Numbers: CA121349, CA94122, CA81436

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (266K)

References

  • 1
    Fujiwara T,Horikoshi H. Troglitazone and related compounds: therapeutic potential beyond diabetes. 2000; 67: 2405–16.
  • 2
    Fujiwara T,Wada M,Fukuda K,Fukami M,Yoshioka S,Yoshioka T,Horikoshi H. Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 1991; 40: 1213–18.
  • 3
    Lehmann JM,Moore LB,Smith-Oliver TA,Wilkison WO,Willson TM,Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor [IMAGE] (PPAR[IMAGE]). J Biol Chem 1995; 270: 12953–6.
  • 4
    Fajas L,Auboeuf D,Raspe E,Schoonjans K,Lefebvre AM,Saladin R,Najib J,Laville M,Fruchart JC,Deeb S,Vidal-Puig A,Flier J, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997; 272: 18779–89.
  • 5
    Mukherjee R,Jow L,Croston GE,Paterniti JR,Jr. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997; 272: 8071–6.
  • 6
    Lefebvre M,Paulweber B,Fajas L,Woods J,McCrary C,Colombel JF,Najib J,Fruchart JC,Datz C,Vidal H,Desreumaux P,Auwerx J. Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol 1999; 162: 331–40.
  • 7
    Su W,Bush CR,Necela BM,Calcagno SR,Murray NR,Fields AP,Thompson EA. Differential expression, distribution, and function of PPARγ in the proximal and distal colon. Physiol Genomics 2007; 30: 342–53.
  • 8
    Yoshizumi T,Ohta T,Ninomiya I,Terada I,Fushida S,Fujimura T,Nishimura G,Shimizu K,Yi S,Miwa K. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 2004; 25: 631–9.
  • 9
    Kato M,Kusumi T,Tsuchida S,Tanaka M,Sasaki M,Kudo H. Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone. J Cancer Res Clin Oncol 2004; 130: 73–9.
  • 10
    Gupta RA,Sarraf P,Mueller E,Brockman JA,Prusakiewicz JJ,Eng C,Willson TM,DuBois RN. Peroxisome proliferator-activated receptor gamma-mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms. J Biol Chem 2003; 278: 22669–77.
  • 11
    Shimada T,Kojima K,Yoshiura K,Hiraishi H,Terano A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 2002; 50: 658–64.
  • 12
    Chen GG,Lee JF,Wang SH,Chan UP,Ip PC,Lau WY. Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. Life Sci 2002; 70: 2631–46.
  • 13
    Bush CR,Havens JM,Necela BM,Su W,Chen L,Yanagisawa M,Anastasiadis PZ,Guerra R,Luxon BA,Thompson EA. Functional genomic analysis reveals cross-talk between peroxisome proliferator-activated receptor gamma and calcium signaling in human colorectal cancer cells. J Biol Chem 2007; 282: 23387–401.
  • 14
    Chen L,Bush CR,Necela BM,Su W,Yanagisawa M,Anastasiadis PZ,Fields AP,Thompson EA. RS5444, a novel PPARgamma agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells. Mol Cell Endocrinol 2006; 251: 17–32.
  • 15
    Kim YS,Cho KO,Lee HJ,Kim SY,Sato Y,Cho YJ. Down syndrome candidate region 1 increases the stability of the IkappaBalpha protein: implications for its anti-inflammatory effects. J Biol Chem 2006; 281: 39051–61.
  • 16
    Kulke MH,Demetri GD,Sharpless NE,Ryan DP,Shivdasani R,Clark JS,Spiegelman BM,Kim H,Mayer RJ,Fuchs CS. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 2002; 8: 395–9.
  • 17
    Kohno H,Yoshitani S,Takashima S,Okumura A,Hosokawa M,Yamaguchi N,Tanaka T. Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats. Jpn J Cancer Res 2001; 92: 396–403.
  • 18
    Tanaka T,Kohno H,Yoshitani S,Takashima S,Okumura A,Murakami A,Hosokawa M. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001; 61: 2424–8.
  • 19
    Osawa E,Nakajima A,Wada K,Ishimine S,Fujisawa N,Kawamori T,Matsuhashi N,Kadowaki T,Ochiai M,Sekihara H,Nakagama H. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003; 124: 361–7.
  • 20
    Yang K,Fan KH,Lamprecht SA,Edelmann W,Kopelovich L,Kucherlapati R,Lipkin M. Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/− double mutant mice. Int J Cancer 2005; 116: 495–9.
    Direct Link:
  • 21
    Lefebvre AM,Chen I,Desreumaux P,Najib J,Fruchart JC,Geboes K,Briggs M,Heyman R,Auwerx J. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998; 4: 1053–7.
  • 22
    Saez E,Tontonoz P,Nelson MC,Alvarez JG,Ming UT,Baird SM,Thomazy VA,Evans RM. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 1998; 4: 1058–61.
  • 23
    Niho N,Takahashi M,Shoji Y,Takeuchi Y,Matsubara S,Sugimura T,Wakabayashi K. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand. Cancer Sci 2003; 94: 960–4.
    Direct Link:
  • 24
    Niho N,Takahashi M,Kitamura T,Shoji Y,Itoh M,Noda T,Sugimura T,Wakabayashi K. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 2003; 63: 6090–5.
  • 25
    Chen L,Necela BM,Su W,Yanagisawa M,Anastasiadis PZ,Fields AP,Thompson EA. Peroxisome proliferator-activated receptor gamma promotes epithelial to mesenchymal transformation by Rho GTPase-dependent activation of ERK1/2. J Biol Chem 2006; 281: 24575–87.
  • 26
    Nissen SE,Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–71.
  • 27
    Murray NR,Davidson LA,Chapkin RS,Clay Gustafson W,Schattenberg DG,Fields AP. Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol 1999; 145: 699–711.
  • 28
    Murray NR,Jamieson L,Yu W,Zhang J,Gokmen-Polar Y,Sier D,Anastasiadis P,Gatalica Z,Thompson EA,Fields AP. Protein kinase Cι is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol 2004; 164: 797–802.
  • 29
    Copland JA,Marlow LA,Kurakata S,Fujiwara K,Wong AK,Kreinest PA,Williams SF,Haugen BR,Klopper JP,Smallridge RC. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 2006; 25: 2304–17.
  • 30
    McLellan EA,Medline A,Bird RP. Dose response and proliferative characteristics of aberrant crypt foci: putative preneoplastic lesions in rat colon. Carcinogenesis 1991; 12: 2093–8.
  • 31
    McLellan EA,Medline A,Bird RP. Sequential analyses of the growth and morphological characteristics of aberrant crypt foci: putative preneoplastic lesions. Cancer Res 1991; 51: 5270–4.
  • 32
    Roncucci L,Stamp D,Medline A,Cullen JB,Bruce WR. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 1991; 22: 287–94.
  • 33
    Shpitz B,Hay K,Medline A,Bruce WR,Bull SB,Gallinger S,Stern H. Natural history of aberrant crypt foci. A surgical approach. Dis Colon Rectum 1996; 39: 763–7.
  • 34
    Matthiessen MW,Pedersen G,Albrektsen T,Adamsen S,Fleckner J,Brynskov J. Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand J Gastroenterol 2005; 40: 198–205.
  • 35
    Sarraf P,Mueller E,Jones D,King FJ,DeAngelo DJ,Partridge JB,Holden SA,Chen LB,Singer S,Fletcher C,Spiegelman BM. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4: 1046–52.
  • 36
    Kitamura S,Miyazaki Y,Shinomura Y,Kondo S,Kanayama S,Matsuzawa Y. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999; 90: 75–80.
  • 37
    Murray NR,Weems C,Chen L,Leon J,Yu W,Davidson LA,Jamieson L,Chapkin RS,Thompson EA,Fields AP. Protein kinase C betaII and TGFbetaRII in omega-3 fatty acid-mediated inhibition of colon carcinogenesis. J Cell Biol 2002; 157: 915–20.
  • 38
    Takahashi M,Nakatsugi S,Sugimura T,Wakabayashi K. Frequent mutations of the beta-catenin gene in mouse colon tumors induced by azoxymethane. Carcinogenesis 2000; 21: 1117–20.
  • 39
    Baek SJ,Wilson LC,Hsi LC,Eling TE. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) ligand selectively induces the early growth response-1 gene independently of PPARgamma. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 2003; 278: 5845–53.
  • 40
    Brunmair B,Gras F,Neschen S,Roden M,Wagner L,Waldhausl W,Furnsinn C. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-γ-mediated changes in gene expression. Diabetes 2001; 50: 2309–15.
  • 41
    Wang C,Fu M,D'Amico M,Albanese C,Zhou J-N,Brownlee M,Lisanti MP,Chatterjee VKK,Lazar MA,Pestell RG. Inhibition of cellular proliferation through IκB kinase-independent and peroxisome proliferator-activated receptor γ-dependent repression of cyclin D1. Mol Cell Biol 2001; 21: 3057–70.
  • 42
    Zhu X,Lin Y,Zhang J,Fu M,Mao Z,Chen YE. Thiazolidinediones, a class of anti-diabetic drugs, inhibit Id2 expression through a PPARgamma-independent pathway in human aortic smooth muscle cells. Cell Mol Life Sci 2003; 60: 212–18.
  • 43
    McAlpine CA,Barak Y,Matise I,Cormier RT. Intestinal-specific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice. Int J Cancer 2006; 119: 2339–46.
    Direct Link:
  • 44
    Batlle E,Verdu J,Dominguez D,del Mont Llosas M,Diaz V,Loukili N,Paciucci R,Alameda F,de Herreros AG. Protein kinase C-alpha activity inversely modulates invasion and growth of intestinal cells. J Biol Chem 1998; 273: 15091–8.
  • 45
    Yokota T,Sugano K,Kondo H,Saito D,Sugihara K,Fukayama N,Ohkura H,Ochiai A,Yoshida S. Detection of aberrant crypt foci by magnifying colonoscopy. Gastrointest Endosc 1997; 46: 61–5.
  • 46
    Takayama T,Katsuki S,Takahashi Y,Ohi M,Nojiri S,Sakamaki S,Kato J,Kogawa K,Miyake H,Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339: 1277–84.
  • 47
    Adler DG,Gostout CJ,Sorbi D,Burgart LJ,Wang L,Harmsen WS. Endoscopic identification and quantification of aberrant crypt foci in the human colon. Gastrointest Endosc 2002; 56: 657–62.
View Full Article (HTML) Get PDF (266K)